- Home
- TRMD vs APLS Comparison
TRMD vs APLS Comparison
Compare TRMD & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | APLS |
|---|---|---|
| Founded | 1889 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TRMD | APLS |
|---|---|---|
| Price | $25.59 | $17.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 21 |
| Target Price | ★ $34.00 | $31.65 |
| AVG Volume (30 Days) | 985.2K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.04% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.21 |
| P/E Ratio | ★ $9.61 | $89.73 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $13.63 | $16.10 |
| 52 Week High | $31.76 | $30.48 |
Technical Indicators
Market Signals| Indicator | TRMD | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 26.16 |
| Support Level | $21.54 | $17.16 |
| Resistance Level | $31.76 | $20.42 |
| Average True Range (ATR) | 0.92 | 0.70 |
| MACD | -0.46 | -0.17 |
| Stochastic Oscillator | 21.03 | 2.53 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM plc operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.